NCT00016081已完成3 期
A Randomized Phase III Study To Evaluate The Safety And Efficacy Or Ribavirin Inhaled Solution In Preventing Progression Of Upper Respiratory Tract Respiratory Syncytial Virus (RSV) Infection To RSV Pneumonia In Blood And Bone Marrow Transplant (BMT) Recipients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 试验地点
- 8
研究概览
简要总结
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective than standard therapy in preventing pneumonia in patients who have respiratory syncytial virus (RSV) infection following stem cell transplantation.
PURPOSE: Randomized phase III trial to compare the effectiveness of ribavirin with that of standard therapy in preventing pneumonia in patients who have RSV infection following stem cell transplantation.
详细描述
OBJECTIVES:
- Compare the efficacy of aerosolized ribavirin vs standard supportive therapy, in terms of preventing progression of upper respiratory tract respiratory syncytial virus (RSV) infection to pneumonia, in patients with RSV following stem cell transplantation.
- Determine the safety of aerosolized ribavirin in this patient population.
OUTLINE: This is a randomized, investigator-blind, controlled, multicenter study. Patients are stratified according to engraftment status (pre vs post) and transplant type (HLA matched-related allogeneic, syngeneic, or autologous vs HLA mismatched-related or unrelated allogeneic). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive standard supportive care for immunocompromised patients with upper respiratory tract infections. Patient also receive aerosolized ribavirin by face mask, mist, or oxygen tent over 2 hours 3 times daily on days 1-10.
- Arm II: Patients receive standard supportive care as in arm I. Treatment continues in the absence of progression to pneumonia or unacceptable toxicity.
Patients are followed at days 14 and 28.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Supportive Care
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Confirmed upper respiratory tract respiratory syncytial virus (RSV) infection documented in nasopharyngeal-throat specimen by rapid antigen test (ELISA), IFA, or shell vial)
- •Signs or symptoms of upper respiratory tract infection (e.g., rhinorrhea and/or low-grade fever (under 101 degrees F with or without evidence of a sore throat)
- •Received prior stem cell transplantation (SCT) and meet one of the following criteria:
- •Between start of conditioning (preparative) regimen and day 90 after allogeneic, autologous, or syngeneic SCT
- •Between days 91 and 180 after unrelated or HLA mismatch-related allogeneic SCT
- •Between days 91 and 180 after SCT with graft-versus-host disease requiring systemic steroids expected to continue throughout study
- •No radiographic evidence of pneumonia
- •PATIENT CHARACTERISTICS:
- •2 and over
- •Performance status:
- •Not specified
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Not specified
- •Not specified
- •Not specified
- •Oxygen saturation 92-100% by pulse oximeter
- •Normal respiratory rate for age
- •No prior adverse reactions to ribavirin
- •No clinical status that would preclude study
- •HIV negative
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 3 months after study
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •See Disease Characteristics
- •No prior immunotherapy for RSV
- •No prior or concurrent RSV hyperimmune globulin or monoclonal antibodies
- •Chemotherapy:
- •Not specified
- •Endocrine therapy:
- •See Disease Characteristics
- •Radiotherapy:
- •Not specified
- •Not specified
- •No prior antiviral drugs with anti-RSV activity
- •Bronchodilator treatment allowed for patients with asthma or a history of reactive airway disease and/or who develop bronchospasm
- •Concurrent ganciclovir, foscarnet, or IV immunoglobulin allowed
- •No mechanical ventilation
- •No other concurrent anti-viral drugs with anti-RSV activity
排除标准
- 未提供
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell TransplantationCancerNCT00014391Fred Hutchinson Cancer Center
终止
3 期
Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant PatientsRespiratory Syncytial Virus InfectionsNCT00031473National Institute of Allergy and Infectious Diseases (NIAID)90
已完成
3 期
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.HIV InfectionNCT01237444Pedro Cahn417
已完成
不适用
A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 with Efavirenz; Each in Combination with Fixed Dose Zidovudine-Lamivudine-B22 Human immunodeficiency virus [HIV] disease resulting in other specified diseasesHuman immunodeficiency virus [HIV] disease resulting in other specified diseasesB22PER-076-00BRISTOL MYERS SQUIBB PERU S.A.,
进行中（未招募）
不适用
Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Parte 2) en pacientes con Hepatitis C crónica de genotipo 1 (aleatorizado, abierto, de fase II)Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with ribavirin for 4 (Part 1) and with or without ribavirin for 24-48 weeks (Part 2) in patients with chronic HCV genotype 1 infection (randomized, open label, Phase II)EUCTR2009-018197-66-ESBoehringer Ingelheim España, S.A.122